Abstract: Adenosine analogue-type A3 receptor agonists having the formula wherein D is N or CH; E is O; X1 is a group of the formula —CR20R2 1-CYCLE, where R20 and R21 are the same or different and are H, F or CH3; CYCLE is where G is N, CH, CF, CCH3 or CCF3, M is H, Y is —O— or N?, and Z is —N? when Y is O, or is O when Y is —N?; R5 is H, CH3, I, Br, Cl, CF3, OH or NH2; and R8 is —NR9R10, —CHR9R10 or —N?CR9R10, where R9 and R10 are the same and are C1-C4 alkyl, C1-C4 alkenyl or C1-C4 alkoxyalkyl X2 is mono-N— or di-N,N—(C1-C4)alkylaminocarbonyl, mono-N—or di-N,N—(C3-C5)cycloalkyl-aminocarbonyl or N-(C1-C4)alkyl-N-(C3-C5)cycloalkylamino-carbonyl; X3 is OH or NH2; X4 is OH; X5 is H , halogen, (C1-C10)alkyl , (C2-C10)alkenyl , (C2-C10)alkynyl , or either of the latter two groups where terminally substituted by an aryl or heteroaryl group and, when having a terminal methyl group, optionally further terminally substituted by hydroxyl.

Abstract: Muscarinic agonists of the formula (I) with M1 selectivity which are useful as agents for stimulating the cognitive functions of the brain.

Abstract: There is disclosed a compound having the formula or a pharmaceutically acceptable salt thereof, wherein: R1a, R1b and R1c are independently fluorine or hydrogen; R2 is C1 to C12 alkyl being straight or branched chain, saturated or unsaturated, mono-substituted or unsubstituted, said substituents being selected from piperidine, pyrroliding, morpholine, thiomorpholine and cycloalkyl of 3 to 7 carbon atoms; a cycloalkyl of 3 to 9 carbon atoms; a cycloalkyl of 3 to 9 carbon atoms having a C1 to C6 alkyl substituent; a polycycloalkyl of 2 to 3 rings having 7 to 12 carbons; and phenyl or phenyl substituted with halogen, hydroxy, C1 to C6 alkoxy, C1 to C6 alkyl, nitro, methylene dioxy or trifluoromethyl; and R3 is a moiety selected from: (I), (II) or a pyrrolidin-3-yl moiety of the formula (III). The compounds are disclosed for use as muscarinic antagonists with M3 selectivity.